Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for July 30, 2021

7/29/2021

 
Announced Research Updates 
 
Aprea Therapeutics announced that in a 12-month, 33 patient, Phase II trial, treatment with eprenetapopt plus azacitidine resulted in relapse free survival of 12.1 months and overall survival of 19.3 months in post-transplant patients with TP53 mutant MDS and AML.
 
NewAmsterdam Pharma (NAP) announced that in the 8-week, 120 patient, Phase II, ROSE trial, patients treated with obicetrapib 10 mg plus a high-intensity statin regimen achieved an LDL reduction of 51% in patients with an LDL-C > 70 mg/dL and triglycerides < 400 mg/dL, who are already being treated with a high-intensity statin. Results have not been announced for obicetrapib 5 mg nor placebo. 
 
Published Research Updates
 
In a separate analysis of the 9-month, 1,222 patient, Phase III, SOLOIST-WHF trial, patients treated with sotagliflozin had 2.9 more days alive and out of the hospital. Sotagliflozin patients had a similar number of hospitalizations compared to the placebo group (38.5% vs. 41.4%), but fewer patients required multiple rehospitalizations (16.3% vs 22%).
 
Interim results after 19-months from the 1,101 patient, Phase II, IPATential150 trial, suggested that ipatasertib, added to abiraterone and prednisone/prednisolone, improved radiographic progression-free survival compared to abiraterone plus prednisone/prednisolone alone (18.5 months vs 16.5 months) in patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN loss, but not in all mCRPC patients regardless of PTEN status. 
 
In the 283 patient, Phase III, EVIDENCE trial, treatment with icotinib resulted in a disease-free survival of 47 months compared to 22.1 months with vinorelbine/cisplatin for adenocarcinoma and squamous carcinoma or pemetrexed/cisplatin for non-squamous carcinoma in Chinese patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer.
 
In a 28-day, 188 patient, Phase II trial, patients treated with oral insulin had a 1.7 mg/dL increase in their mean night-time continuous glucose monitoring (CGM) levels compared to a 13.7 mg/dL increase with placebo in type 2 diabetics receiving metformin.
 
In a 52-week, 741 patient, open-label, Phase III trial, patients treated with roxadustat increased hemoglobin by 0.39 g/dL compared to a 0.09 g/dL decrease with epoetin alfa in dialysis-dependent CKD patients with anemia, who were receiving erythropoiesis-stimulating agents. In a 24-week, 334 Japanese patient, open-label, Phase III trial, the change in average hemoglobin with roxadustat was non-inferior to darbepoetin alfa (-0.07 g/dl difference) in non-dialysis-dependent CKD patients with anemia, who were receiving erythropoiesis-stimulating agents.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.